NO20020130L - Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis - Google Patents

Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Info

Publication number
NO20020130L
NO20020130L NO20020130A NO20020130A NO20020130L NO 20020130 L NO20020130 L NO 20020130L NO 20020130 A NO20020130 A NO 20020130A NO 20020130 A NO20020130 A NO 20020130A NO 20020130 L NO20020130 L NO 20020130L
Authority
NO
Norway
Prior art keywords
cell migration
fviia
chemotaxis
gene expression
tissue factor
Prior art date
Application number
NO20020130A
Other languages
English (en)
Norwegian (no)
Other versions
NO20020130D0 (no
Inventor
Mirella Ezban
Lars Christian Petersen
Agneta Siegbahn
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20020130D0 publication Critical patent/NO20020130D0/no
Publication of NO20020130L publication Critical patent/NO20020130L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
NO20020130A 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis NO20020130L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA199901023 1999-07-14
US14830099P 1999-08-11 1999-08-11
DKPA199901117 1999-08-12
PCT/DK2000/000401 WO2001005353A2 (en) 1999-07-14 2000-07-14 USE OF FVIIa OR A TISSUE FACTOR ANTAGONIST FOR REGULATING GENE EXPRESSION AND CELL MIGRATION OR CHEMOTAXIS

Publications (2)

Publication Number Publication Date
NO20020130D0 NO20020130D0 (no) 2002-01-11
NO20020130L true NO20020130L (no) 2002-03-13

Family

ID=27221063

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020130A NO20020130L (no) 1999-07-14 2002-01-11 Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis

Country Status (19)

Country Link
US (3) US20020193302A1 (de)
EP (1) EP1200116B1 (de)
JP (1) JP2003525028A (de)
KR (1) KR100821644B1 (de)
CN (1) CN100411684C (de)
AT (1) ATE411041T1 (de)
AU (1) AU5807500A (de)
BR (1) BR0012408A (de)
CA (1) CA2378249A1 (de)
CZ (1) CZ200240A3 (de)
DE (1) DE60040539D1 (de)
ES (1) ES2316372T3 (de)
HU (1) HUP0302052A3 (de)
IL (1) IL147294A0 (de)
MX (1) MXPA02000468A (de)
NO (1) NO20020130L (de)
PL (1) PL353035A1 (de)
RU (1) RU2268744C2 (de)
WO (1) WO2001005353A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271365A1 (en) * 2000-06-21 2002-01-02 Wyeth Cyr61 as a target for treatment and diagnosis of breast cancer
DE10238429A1 (de) 2002-03-19 2003-10-30 Aventis Behring Gmbh Intellect Marburg I Mutante der Faktor VII aktivierenden Protease (FSAP) als Risikofaktor für Atherosklerose
US6858587B2 (en) 2001-11-02 2005-02-22 Novo Nordisk Pharmaceuticals, Inc. Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
AU2002336920A1 (en) * 2001-11-02 2003-05-12 Novo Nordisk Health Care Ag Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
WO2003065871A2 (en) * 2002-02-04 2003-08-14 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
AU2004284013A1 (en) * 2003-08-06 2005-05-06 Sirnasense As The use of siRNA silencing in the prevention of metastasis
US20070207154A1 (en) * 2004-04-16 2007-09-06 Martin Friedlander Method of modulating vascularization
NZ568762A (en) * 2005-11-07 2011-11-25 Scripps Research Inst Use of an inhibitor of tissue factor signaling in the manufacture of a medcament for inhibiting or suppressing tissue factor/tissue factor VIIa signaling involving protease activated receptor 2 in a mammal
US20100015160A1 (en) * 2007-02-21 2010-01-21 Yale University Compositions and methods for diagnosing and treating endometriosis
JP5905258B2 (ja) * 2011-07-01 2016-04-20 株式会社 資生堂 血小板由来成長因子−ｂｂ産生亢進剤、並びにそれを含む間葉系幹細胞産生促進剤、幹細胞安定化剤、及び真皮再生化剤
CN109381478A (zh) * 2018-10-31 2019-02-26 青岛大学附属医院 一种miRNA在制备抑制新生血管生成和抑制VEGF-A因子表达的试剂中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2123338C1 (ru) * 1990-06-15 1998-12-20 Сайтел Корпорейшн Фармацевтическая композиция на основе медиатора межклеточной адгезии (варианты), способ ингибирования межклеточной адгезии, способ лечения воспалительного заболевания, способ анализа тестируемого соединения на способность ингибировать клеточную адгезию, способ получения соединения
WO1993006855A1 (en) 1991-10-11 1993-04-15 Novo Nordisk A/S Hemostatic composition for local hemostasis
DE19538715A1 (de) * 1995-10-18 1997-04-30 Behringwerke Ag Verfahren zur Reinigung von Faktor VII und aktiviertem Faktor VII
US6413735B1 (en) 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
AU7907398A (en) 1997-06-23 1999-01-04 Novo Nordisk A/S Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function
ES2339196T3 (es) 1997-07-18 2010-05-17 Novo Nordisk Health Care Ag Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente.
US20030040481A1 (en) * 1997-07-18 2003-02-27 Lars Kongsbak Methods for modifying cell motility using a factor VIIa antagonist
AT408613B (de) * 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
US7015194B2 (en) * 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
CZ20032454A3 (en) 2001-03-22 2004-03-17 Novo Nordisk Health Care Ag Coagulation factor vii derivative
AU2002338487A1 (en) 2001-05-02 2002-11-11 Novo Nordisk A/S Modified fvii in treatment of ards
AU2002354846B2 (en) 2001-07-20 2007-08-02 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
WO2003039590A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
WO2003039581A1 (en) 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid
JP2006510568A (ja) 2001-11-09 2006-03-30 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子ポリペプチドおよびイプシロン―アミノカプロン酸を含む薬学的組成物
CN1596125A (zh) 2001-11-09 2005-03-16 诺和诺德医疗保健公司 包括因子ⅶ多肽和因子ⅴ多肽的药物组合物

Also Published As

Publication number Publication date
CZ200240A3 (cs) 2003-04-16
MXPA02000468A (es) 2008-10-06
CN1460024A (zh) 2003-12-03
EP1200116B1 (de) 2008-10-15
RU2268744C2 (ru) 2006-01-27
KR100821644B1 (ko) 2008-04-11
US7829529B2 (en) 2010-11-09
CA2378249A1 (en) 2001-01-25
ATE411041T1 (de) 2008-10-15
WO2001005353A2 (en) 2001-01-25
DE60040539D1 (de) 2008-11-27
CN100411684C (zh) 2008-08-20
NO20020130D0 (no) 2002-01-11
HUP0302052A3 (en) 2005-12-28
JP2003525028A (ja) 2003-08-26
WO2001005353A3 (en) 2001-07-19
AU5807500A (en) 2001-02-05
IL147294A0 (en) 2002-08-14
PL353035A1 (en) 2003-10-06
BR0012408A (pt) 2002-03-12
US20050239708A1 (en) 2005-10-27
HUP0302052A2 (hu) 2003-09-29
US20090036378A1 (en) 2009-02-05
US20020193302A1 (en) 2002-12-19
ES2316372T3 (es) 2009-04-16
KR20020025194A (ko) 2002-04-03
EP1200116A2 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
DE50310980D1 (de) VERWENDUNG VON I kappa B-KINASE INHIBITOREN IN DER SCHMERZTHERAPIE
NO20020130L (no) Anvendelse av FVIIa eller en vevsfaktorantagonist til regulering av genekspresjon og cellemigrasjon eller kjemotaksis
NO961888D0 (no) Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer av metallproteinaser
EP1581056A4 (de) Therapeutische retrovirus-vektoren für diegentherapie
DE60021266D1 (de) Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
ATE368731T1 (de) Menschliche cd45+ und/oder fibroblasten+ mesenchymale stammzellen
DE60222671D1 (de) Thienopyrimidinedione und deren verwendung in der behandlung von autoimmunerkrankungen
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
ATE324105T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung von entzündungserkrankungen von kopf und nacken
ATE452185T1 (de) Dimethylarginin-dimethylaminohydrolasen
MX2009004051A (es) Uso de antagonistas de il-1 para tratar gota y pseudo gota.
DK1218494T3 (da) Præparater og fremgangsmåder til inhibering af C2-cellecyklusstandsning og sensibilisering af celler til DNA-beskadigende midler
DE69738887D1 (de) Tumor necrosis factor rezeptor abspaltendes enzym, dessen zubereitungen und verwendungen
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
DE60327084D1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-ä1,3,4-oxadiazol-2-ylüphenyl)pyridin-3-sulphonamid in der tumortherapie
ATE362923T1 (de) 4-(phenylpiperazinylmethyl)benzamidderivate und deren verwendung zur behandlung von schmerzen oder gastrointestinalen erkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
ATE242641T1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)- antagonisten und inhibitoren der hautmastzell- degranulation
ATE206052T1 (de) Verwendung von sphingosin-1-phosphat, sphingosin- 1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
WO2003037361A3 (en) Use of tissue factor agonist or tissue factor antagonist for treatment of conditions related to apoptosis
ATE198271T1 (de) Syndecan-stimulierung der zellulären differenzierung
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
MXPA04011018A (es) Nueva combinacion de inhibidores reversibles de la bomba de protones y productos terapueticos para tratar trastornos de las vias respiratorias.
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen